LONDON (Alliance News) - Respiratory drug company Vectura Group PLC on Friday said it has completed the phase-one clinical study evaluating its VR942 inhaled asthma treatment.
The study met the primary objective of evaluating the safety and tolerability of once-daily doses of the treatment, showing VR942 was safe and well-tolerated.
The data from the trial will support the continued development of VR942 in severe inflammatory respiratory disease and progressing the drug to phase two trials.
"The generation of data indicating a positive impact on biomarkers of inflammation presents an exciting prospect both for this antibody specifically and as a potential platform for other biologic developments in the future," said Vectura Chief Executive James Ward-Lilley.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
